Invivyd is an antibody-based viral infectious disease company on a mission to transcend the limitations of the human immune system. The company is developing engineered antibodies to provide durable protection from viral infectious diseases, beginning with COVID-19. Working at the intersection of evolutionary virology, human immunology and predictive modeling, Invivyd’s discovery platform is designed to identify antibodies to target parts of the virus least pressured to mutate, thereby increasing the likelihood of sustained utility. Its product candidates are being developed for use in prevention and treatment of disease and optimized for potency and breadth of protection across strains.

The firm’s platform approach has generated a pipeline of antibody-based solutions for COVID-19 and other viral infectious diseases. This includes multiple next-generation antibodies for the prevention and treatment of COVID-19, starting with NVD200, a combination product candidate expected to enter the clinic in Q1 2023. Adintrevimab, was shown to provide neutralizing protection against SARS-CoV-2 for all variants of concern until the emergence of the Omicron BA2 strain and its sublineages. Invivyd has applied its discovery technology to “re-engineer” adintrevimab to evolve and identify multiple next generation antibody candidates that provide broad neutralization in vitro against past and current variants of concern, including Omicron BA1, BA2, BA.4, BA.5, BA2.75 and sublineages.